Patents Represented by Attorney, Agent or Law Firm Lisa A. Haile
  • Patent number: 6677307
    Abstract: Disclosed are TGF-60 mimetics that PEGylated TGF-&agr; polypeptides and PEGylated TGF-60 related polypetides or fragments thereof.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: January 13, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell, John M. Reno
  • Patent number: 6677115
    Abstract: Disclosed is a process of screening clones having DNA from an uncultivated microorganism for a specified protein, e.g. enzyme, activity by screening for a specified protein, e.g. enzyme, activity in a library of clones prepared by (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and (ii) transforming a host with recovered DNA to produce a library of clones which is screened for the specified protein, e.g. enzyme, activity.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: January 13, 2004
    Assignee: Diversa Corporation
    Inventor: Jay M. Short
  • Patent number: 6673534
    Abstract: Methods for detecting allelic variants of the myostatin (growth and differentiation factor-8) gene are provided. Specifically provided are methods of identifying subjects having or having a predisposition for increased muscle mass as compared to subjects having wild-type myostatin. Increased muscle mass is particularly desirable for identification of animals used to produce food products, including bovine, porcine, ovine, avian and piscine species.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: January 6, 2004
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Se-Jin Lee, Alexander C. McPherron
  • Patent number: 6673066
    Abstract: The present invention may be embodied in a technique for elimination of vulnerable plaque in a vessel. Vulnerable plaque is detected in the vessel based on a temperature increase of the vessel's wall and treated using cryoablation.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: January 6, 2004
    Assignee: Cardiostream, Inc.
    Inventor: Randell L. Werneth
  • Patent number: 6660844
    Abstract: A chimeric protein sensor including an optically active polypeptide linked to a responsive polypeptide, or responsive fragment thereof, which undergoes a change in response to a cell signaling event, wherein an optical property of the sensor is altered in response to the change in the responsive polypeptide, or responsive fragment thereof is provided, as well as nucleic acid sequences encoding the chimeric protein sensor. The chimeric protein sensor includes an optically active polypeptide or fragment thereof, such as green fluorescent protein (GFP), for measuring cellular events in vivo.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: December 9, 2003
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Micah S. Siegel, Ehud Y. Isacoff
  • Patent number: 6656475
    Abstract: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: December 2, 2003
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Se-Jin Lee, Alexandra C. McPherron
  • Patent number: 6656677
    Abstract: Recombinant enzyme libraries and kits where a plurality of enzymes are each characterized by different physical and/or chemical characteristics and classified by common characteristics. The characteristics are determined by screening of recombinant enzymes expressed by a DNA library produced from various microorganisms.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: December 2, 2003
    Assignee: Diversa Corporation
    Inventor: Jay M. Short
  • Patent number: 6654636
    Abstract: The present invention describes an in vivo method, using pulsed electric field to deliver therapeutic agents into cells of the skin and muscle for local and systemic treatments. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: November 25, 2003
    Assignee: Genetronics, Inc.
    Inventors: Nagendu B. Dev, Gunter A. Hofmann, Edward Nolan, Dietmar P. Rabussay, Arnt Tonnessen, Georg Widera, Lei Zhang
  • Patent number: 6649350
    Abstract: Compositions and methods for electrochemical detection and localization of genetic point mutations, common DNA lesions and other base-stacking perturbations within oligonucleotide duplexes adsorbed onto electrodes and their use in biosensing technologies are described. An intercalative, redox-active moiety (such as an intercalator or nucleic acid-binding protein) is adhered and/or crosslinked to immobilized DNA duplexes at different separations from an electrode and probed electrochemically in the presence or absence of a non-intercalative, redox-active moiety. Interruptions in DNA-mediated electron-transfer caused by base-stacking perturbations, such as mutations or binding of a protein to its recognition site are reflected in a difference in electrical current, charge and/or potential.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: November 18, 2003
    Assignee: California Institute of Technology
    Inventors: Jacqueline K. Barton, Elizabeth M. Boon, Shana O. Kelley, Michael G. Hill
  • Patent number: 6638756
    Abstract: The invention chimeric organism comprises a chimeric surface integrin-like fusion protein in which the I domain has been replaced by an antibody fragment that binds a disease-associated antigen on a cell. Binding of the antibody fragment to the disease-associated antigen triggers virulent transformation of the chimeric pathogenic organism so as to cause the organism to infiltrate the target cell with specificity. Preferably, the chimeric organism is a chimeric pathogenic C. albicans having an INT1 fusion protein in which the I domain is replaced by an antibody fragment, preferably a single chain antibody, and in which expression of an iron transporter gene necessary for infiltration of a target cell is triggered under the control of a EFG1p response element. Binding of the antibody to the disease-associated antigen causes filamentous transformation in the chimeric pathogenic C. albicans and specific infiltration of target cells.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: October 28, 2003
    Assignee: California Institute of Technology
    Inventor: Duncan Odom
  • Patent number: 6635480
    Abstract: Growth differentiation factor, Lefty-2, is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the Lefty-2 polypeptide and polynucleotide sequences.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: October 21, 2003
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Se-Jin Lee, Thanh Huynh, Suzanne Sebald
  • Patent number: 6610505
    Abstract: An isolated polypeptide (JNK characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: August 26, 2003
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Masahiko Hibi, Anning Lin
  • Patent number: 6610528
    Abstract: A method and device for collection and concentration of microbes via selectively attracting microbes to specific substrates chemically conjugated to a solid surface, such as a particle, are provided. Further, a method for selectively enriching for specific microorganisms using a device for collecting populations of microorganisms from an environmental sample comprising a solid support having a surface for attachment of an enrichment media is provided. The method for selectively enriching one or more populations of microorganisms from an in situ environment includes providing a device which has a container having a plurality of solid support particles in the container and a selective microbial enrichment media chemically attached thereto the particles. The container also has permeable openings for the microorganisms to provide entry of them therein so that the microbes will contact the enrichment media.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: August 26, 2003
    Assignee: Diversa Corporation
    Inventors: Eric J. Mathur, Jeffrey L. Stein, Martin Keller, Karl Rusterholz
  • Patent number: 6607884
    Abstract: The present invention relates to a method for detecting a polynucleotide encoding GDF-8 in a sample by contacting the sample with an oligonucleotide probe that hybridizes specifically with a polynucleotide encoding GDF-8; and detecting specific hybridization of the oligonucleotide probe to a polynucleotide in the sample, thereby detecting a polynucleotide encoding GDF-8 in the sample. The sample can be a tissue sample or a cell sample, for example, a muscle cell sample, which can be obtained, for example, from a mammal such as a bovine, ovine or porcine mammal, or a human.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: August 19, 2003
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Se-Jin Lee, Alexandra C. McPherron
  • Patent number: 6602675
    Abstract: Disclosed is a process for identifying clones having a specified activity of interest, which process comprises (i) generating one or more expression libraries derived from nucleic acid directly isolated from the environment; and (ii) screening said libraries utilizing a fluorescence activated cell sorter to identify said clones. More particularly, this is a process for identifying clones having a specified activity of interest by (i) generating one or more expression libraries derived from nucleic acid directly or indirectly isolated from the environment; (ii) exposing said libraries to a particular substrate or substrates of interest; and (iii) screening said exposed libraries utilizing a fluorescence activated cell sorter to identify clones which react with the substrate or substrates.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: August 5, 2003
    Assignee: Diversa Corporation
    Inventors: Jay M. Short, Martin Keller
  • Patent number: 6599695
    Abstract: A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: July 29, 2003
    Inventors: Fred H. Gage, Jasodhara Ray
  • Patent number: 6596493
    Abstract: Methods are provided for detecting a cell proliferative disorder associated with TSLC1 by contacting a proliferating cell of a subject suspected of having the disorder with a reagent that detects TSLC1 and detecting the level of TSLC1 in the proliferating cell. TSLC1 is a single gene whose expression is reduced or absent in A549 and some other NSCLC, hepatocellular carcinoma and pancreatic cancer cell lines. It has further been discovered that TSLC1 expression or suppression is perfectly correlated with promoter methylation state. Restoration of TSLC1 expression to normal or higher levels is sufficient by itself to suppress tumor formation. The invention further provides methods of treating such disorders by contacting cells of a patient suffering from the disorder with a therapeutically effective amount of a reagent that modulates TSLC1 level in the proliferating cells.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: July 22, 2003
    Assignees: The Johns Hopkins University School of Medicine, National Cancer Center Research Institute
    Inventors: Roger Harper Reeves, Yoshinori Murakami
  • Patent number: 6596522
    Abstract: Methods and compositions are provided for determining the potential of a membrane. In one aspect, the method comprises: (a) introducing a first reagent comprising a hydrophobic fluorescent ion capable of redistributing from a first face of the membrane to a second face of the membrane in response to changes in the potential of the membrane, as described by the Nernst equation, (b) introducing a second reagent which labels the first face or the second face of the membrane, which second reagent comprises a chromophore capable of undergoing energy transfer by either (i) donating excited state energy to the fluorescent ion, or (ii) accepting excited state energy from the fluorescent ion, (c) exposing the membrane to radiation; (d) measuring energy transfer between the fluorescent ion and the second reagent, and (e) relating the energy transfer to the membrane potential. Energy transfer is typically measured by fluorescence resonance energy transfer.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: July 22, 2003
    Assignee: The Regents of the University of California
    Inventors: Roger Y. Tsien, Jesus E. Gonzalez, III
  • Patent number: 6593135
    Abstract: Engineered fluorescent proteins, nucleic acids encoding them and methods of use.
    Type: Grant
    Filed: May 19, 2000
    Date of Patent: July 15, 2003
    Assignee: The State of Oregon, Acting by and Through the State Board of Higher Education on Behalf of the University of Oregon
    Inventors: Rebekka M. Wachter, S. James Remington
  • Patent number: 6586207
    Abstract: Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallyglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: July 1, 2003
    Assignee: California Institute of Technology
    Inventors: David A. Tirrell, Kristi Lynn Kiick